BUDGET IMPACT OF DURVALUMAB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE STAGE III NONSMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

被引：0
|
作者：
Meirelles, I [1 ]
Costa, N. [1 ]
Dias, C. [2 ]
Massaoka, M. [2 ]
Lopes, D. G. [2 ]
Jabase, L. [3 ]
机构：
[1] IQVIA Real World Insights, Sao Paulo, SP, Brazil
[2] AstraZeneca, Cotia, Brazil
[3] AstraZeneca, Cotia, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE386
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 50 条
  • [1] Preoperative concurrent chemoradiotherapy for unresectable stage III nonsmall cell lung cancer
    Milstein, D
    Kuten, A
    Saute, M
    Best, LA
    Daoud, K
    ZenAlDeen, I
    Dale, J
    Robinson, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (05): : 1125 - 1132
  • [2] Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
    Huber, Rudolf M.
    Reck, Martin
    Thomas, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (04) : 1119 - 1133
  • [3] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [4] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [5] The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
    Cerqueira, Erica R.
    Batista, Paula M.
    Almeida, Milena F.
    Rego, Maria A. C.
    Ribeiro-Pereira, Ana C. P.
    Alencar, Fernando
    Fernandes, Roberta A.
    Calabrich, Aknar F. C.
    Schvartsman, Gustavo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice
    Furuhashi, K.
    Hataji, O.
    Nakamura, Y.
    Suzuki, Y.
    Sakaguchi, T.
    Ito, K.
    Fujiwara, K.
    Nishii, Y.
    Taguchi, O.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1104 - S1104
  • [7] Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer
    Chu Chia-Hsun
    Chiu Tzu-Hsuan
    Wang Chin-Chou
    Chang Wen-Chen
    Huang Allen Chung-Cheng
    Liu Chien-Ying
    Wang Chih-Liang
    Ko Ho-Wen
    Chung Fu-Tsai
    Hsu Ping-Chih
    Guo Yi-Ke
    Kuo, Chih-Hsi S.
    Yang Cheng-Ta
    THORACIC CANCER, 2020, 11 (06) : 1541 - 1549
  • [8] Treatment Outcome and Safety of Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Kim, S.
    Kim, N.
    Chung, S.
    Choi, J.
    Hyun, I.
    Yeo, Y.
    Park, J.
    Jang, S.
    Kim, T.
    Sim, Y.
    Lee, C.
    Kim, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [9] Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era
    Mccall, N. S.
    McGinnis, H. S.
    Janopaul-Naylor, J. R.
    Kesarwala, A. H.
    Tian, S.
    Stokes, W. A.
    Shelton, J. W.
    Steuer, C. E.
    Carlisle, J. W.
    Leal, T.
    Ramalingam, S. S.
    Bradley, J. D.
    Higgins, K. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S109
  • [10] Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era
    McCall, Neal S.
    McGinnis, Hamilton S.
    Janopaul-Naylor, James R.
    Kesarwala, Aparna H.
    Tian, Sibo
    Stokes, William A.
    Shelton, Joseph W.
    Steuer, Conor E.
    Carlisle, Jennifer W.
    Leal, Ticiana
    Ramalingam, Suresh S.
    Bradley, Jeffrey D.
    Higgins, Kristin A.
    RADIOTHERAPY AND ONCOLOGY, 2022, 174 : 133 - 140
12345